Fluoroquinolone Enhances the Mutation Frequency for Meropenem-Selected Carbapenem Resistance in Pseudomonas aeruginosa, but Use of the High-Potency Drug Doripenem Inhibits Mutant Formation

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2008-08-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.00464-08PMID 18694945PMCID PMC2565900
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

  2020cited by this paper
• Copyright © 2004, American Society for Microbiology In Vitro Antimicrobial Activity of Doripenem, a New Carbapenem

  2008cited by this paper
• Potency of Carbapenems for the Prevention of Carbapenem-Resistant Mutants of Pseudomonas aeruginosa

  2006cited by this paper
• Pyrosequencing for rapid identification of carbapenem-hydrolysing OXA-type beta-lactamases in Acinetobacter baumannii.

  2006cited by this paper
• Rapid nested PCR-based detection of Ramularia collo-cygni direct from barley.

  2006cited by this paper
• Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR.

  2006cited by this paper
• Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.

  2005cited by this paper
• Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina.

  2005cited by this paper
• Metallo-beta-lactamase-producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan.

  2004cited by this paper
• Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential

  2004cited by this paper
• Of Pseudomonas, porins, pumps and carbapenems.

  2001cited by this paper
• MexR Repressor of the mexAB-oprMMultidrug Efflux Operon of Pseudomonas aeruginosa: Identification of MexR Binding Sites in the mexA-mexRIntergenic Region

  2001cited by this paper
• Carbapenem Resistance Mechanisms in Pseudomonas aeruginosa Clinical Isolates

  2001cited by this paper
• Carbapenem Activities against Pseudomonas aeruginosa: Respective Contributions of OprD and Efflux Systems

  1999cited by this paper
• Synthesis and modification of a novel 1β-methyl carbapenem antibiotic, S-4661

  1996cited by this paper
• Synthesis and modification of a novel 1 beta-methyl carbapenem antibiotic, S-4661.

  1996cited by this paper
• Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.

  1995cited by this paper
• Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa

  1995cited by this paper
• Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance

  1994cited by this paper
• Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center

  1994cited by this paper
• Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays

  1993cited by this paper
• Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group

  1993cited by this paper
• Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients.

  1992cited by this paper
• Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa

  1992cited by this paper
• Cloning and analysis of the gene (rpoDA) for the principal sigma factor of Pseudomonas aeruginosa.

  1991cited by this paper
• Cloning and analysis of the gene (rpoDA) for the principal σ factor of Pseudomonas aeruginosa

  1991cited by this paper
• Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa

  1990cited by this paper
• Decreased outer membrane permeability in imipenem-resistant mutants of Pseudomonas aeruginosa

  1989cited by this paper
• Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein

  1987cited by this paper
• Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections.

  1986cited by this paper
• Properties of the penicillin-binding proteins of Escherichia coli K12,.

  1977cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• Antibiotic Resistance in Klebsiella pneumoniae and Related Enterobacterales: Molecular Mechanisms, Mobile Elements, and Therapeutic Challenges

  2026cites this paper
• Risk factors for multidrug-resistant and carbapenem-resistant Klebsiella pneumoniae bloodstream infections in Shanghai: A five-year retrospective cohort study

  2025cites this paper
• Ciprofloxacin pre-exposure influences individual cell MIC and heteroresistance of bacteria inside microfluidic droplets

  2025cites this paper
• Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns

  2025cites this paper
• Antimicrobial Resistance and Mortality in Carbapenem-Resistant Pseudomonas aeruginosa Infections in Southern Thailand

  2025cites this paper
• Impact of meropenem exposure on fluoroquinolone and carbapenem resistance in Pseudomonas aeruginosa infection in inpatients in a Japanese university hospital: Insights into oprD mutations and efflux pump overexpression.

  2025cites this paper
• Mutational signature analysis predicts bacterial hypermutation and multidrug resistance

  2025cites this paper
• Assessing the impact of meropenem exposure on ceftolozane/tazobactam-resistance development in Pseudomonas aeruginosa using in vitro serial passage.

  2024cites this paper
• The SOS Response Activation and the Risk of Antibiotic Resistance Enhancement in Proteus spp. Strains Exposed to Subinhibitory Concentrations of Ciprofloxacin

  2024cites this paper
• Clinical impact and early prediction of carbapenem-resistant Pseudomonas aeruginosa bacteremia in allogeneic hematopoietic stem cell transplantation.

  2023cites this paper
• Antimicrobial prophylaxis in decompensated cirrhosis: friend or foe?

  2023cites this paper
• Case Report: Whole-Genome Sequencing of Serially Collected Haemophilus influenzae From a Patient With Common Variable Immunodeficiency Reveals Within-Host Evolution of Resistance to Trimethoprim-Sulfamethoxazole and Azithromycin After Prolonged Treatment With These Antibiotics

  2022cites this paper
• Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates

  2022cites this paper
• RecA and Specialized Error-Prone DNA Polymerases Are Not Required for Mutagenesis and Antibiotic Resistance Induced by Fluoroquinolones in Pseudomonas aeruginosa

  2022cites this paper
• Boosting Antibiotics Performance by New Formulations with Deep Eutectic Solvents.

  2022cites this paper
• The Pseudomonas aeruginosa substrate-binding protein Ttg2D functions as a general glycerophospholipid transporter across the periplasm

  2021cites this paper
• Critical points and potential pitfalls of outbreak of IMP-1-producing carbapenem-resistant Pseudomonas aeruginosa among kidney transplant recipients: a case-control study.

  2021cites this paper
• High potency of sequential therapy with only β-lactam antibiotics

  2021cites this paper
• Maximum levels of cross‐contamination for 24 antimicrobial active substances in non‐target feed.
Part 10: Quinolones: flumequine and oxolinic acid

  2021cites this paper
• Risk Factors for and Clinical Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Nosocomial Infections: A Retrospective Study in a Tertiary Hospital in Beijing, China

  2021cites this paper
• Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review.

  2020cites this paper
• Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones in vitro: a systematic review of the literature

  2020cites this paper
• Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis.

  2020cites this paper
• Issues beyond resistance: inadequate antibiotic therapy and bacterial hypervirulence

  2020cites this paper
• The effect of an antimicrobial stewardship programme in two intensive care units of a teaching hospital: an interrupted time series analysis.

  2020cites this paper
• The Ttg2 ABC system in Pseudomonas aeruginosa functions as a general glycerophospholipid transporter between the two cell membranes

  2020cites this paper
• Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.

  2019cites this paper
• Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem.

  2019cites this paper
• Susceptibility of carbapenem-resistant Pseudomonas aeruginosa clinical isolates to novel cephalosporin antibiotics

  2019cites this paper
• Evolution toward maximum transport capacity of the Ttg2 ABC system in Pseudomonas aeruginosa

  2019cites this paper
• Antibiotic-Induced Genetic Variation: How It Arises and How It Can Be Prevented.

  2018cites this paper
• In vitro and In vivo characterization of anti-biofilm activity of LpxC inhibitor alone, and in combination with different classes of antimicrobials

  2018cites this paper
• Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.

  2018cites this paper
• Risk Factors for Carbapenem-resistant Klebsiella pneumoniae Infection and Mortality of Klebsiella pneumoniae Infection

  2018cites this paper
• Investigation of genotoxic effects of doripenem using cytogenetic and molecular methods.

  2017cites this paper
• Investigating azoreductases and NAD(P)H dependent quinone oxidoreductases in Pseudomonas aeruginosa

  2017cites this paper
• The Impact of Antibiotic Stewardship Programs in Combating Quinolone Resistance: A Systematic Review and Recommendations for More Efficient Interventions

  2017cites this paper
• Persistence and Adaptation of Pseudomonas Aeruginosa in cystic Fibrosis Airway

  2017cites this paper
• Risk factors for and role of OprD protein in increasing minimal inhibitory concentrations of carbapenems in clinical isolates of Pseudomonas aeruginosa

  2017cites this paper
• Mutational Consequences of Ciprofloxacin in Escherichia coli

  2016cites this paper
• Mutational Consequences of Ciprofloxacin in Escherichia coli

  2016cites this paper
• Pseudomonas aeruginosa: targeting cell-wall metabolism for new antibacterial discovery and development.

  2016cites this paper
• Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections.

  2016cites this paper
• Effect of Standard Post-harvest Interventions on the Survival and Regrowth of Antibiotic-Resistant Bacteria on Fresh Produce

  2016cites this paper
• The phenotypic evolution of Pseudomonas aeruginosa populations changes in the presence of subinhibitory concentrations of ciprofloxacin.

  2016cites this paper
• Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.

  2015cites this paper
• Shortening the course of antibiotic treatment in the intensive care unit

  2015cites this paper
• Usefulness of Continuous Regional Arterial Infusion with Doripenem and Protease Inhibitors for Severe Acute Pancreatitis

  2015cites this paper
• Resistance and Response to Anti-Pseudomonas Agents and Biocides

  2015cites this paper
• The β‐Lactams Strike Back: Ceftazidime‐Avibactam

  2015cites this paper
• Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator

  2015cites this paper
• Regulation of Outer Membrane Porins in P. aeruginosa Strains Collected from Patients with Cystic Fibrosis

  2014cites this paper
• Responses of Pseudomonas aeruginosa to antimicrobials

  2014cites this paper
• [Sources of antibiotics in natural environments and their biological role].

  2014cites this paper
• Antibiotics and antibiotic resistance: a bitter fight against evolution.

  2013cites this paper
• The multifaceted roles of antibiotics and antibiotic resistance in nature

  2013cites this paper
• Identification of Novel Genes Responsible for Overexpression of ampC in Pseudomonas aeruginosa PAO1

  2013cites this paper
• Antibiotics in the environment: the possible inadvertent effect on human morbidity & mortality.

  2013cites this paper
• Pseudomonas Aeruginosa AmpR Transcriptional Regulatory Network

  2013cites this paper
• A comparative analysis of meropenem and doripenem in febrile patients with hematologic malignancies: a single-center retrospective study.

  2012cites this paper
• Antimicrobials as promoters of genetic variation.

  2012cites this paper
• Correlation between the consumption of meropenem or doripenem and meropenem susceptibility of Pseudomonas aeruginosa in a university hospital in Japan.

  2012cites this paper
• Changes in gram negative microorganisms’ resistance pattern during 4 years period in a referral teaching hospital; a surveillance study

  2012cites this paper
• Global regulation of the Lon protease of Pseudomonas aeruginosa and its influence on ciprofloxacin resistance and virulence

  2012cites this paper
• Beta-Lactam Resistance Mechanisms in Pseudomonas aeruginosa Strains Causing Bloodstream Infections: Comparative Results Between Brazilian and American Isolates

  2012cites this paper
• Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies.

  2012influential citation
• Clinical efficacy of i.v. doripenem, a new class of carbapenem, in patients with biliary tract infection: A multicenter trial

  2011cites this paper
• Nozokomiyal Pseudomonas Aeruginosa İzolatlarinda Doripenem Duyarlilik Oranlarinin E-Test Yöntemiyle Araştirilmasi Investigation of Doripenem Sensitivity by e-Test Method in Nosocomial Isolates of Pseu- domanas Aeruginosa

  2011cites this paper
• In Vitro Activity Studies of Doripenem and Two Other Carbapenems Tested Against Pseudomonas aeruginosa and Other Non-Fermentative Bacilli

  2011cites this paper
• Combination Antibiotic Therapy for Empiric and Definitive Treatment of Gram‐Negative Infections: Insights from the Society of Infectious Diseases Pharmacists

  2011cites this paper
• Pseudomonas aeruginosa: all roads lead to resistance.

  2011cites this paper
• Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.

  2011cites this paper
• Actividad comparativa in vitro de doripenem y de otros carbapenemes frente a Pseudomonas aeruginosa

  2010cites this paper
• [In vitro activity of doripenem and other carbapenems against Pseudomonas aeruginosa].

  2010cites this paper
• Fluoroquinolone prophylaxis against febrile neutropenia in areas with high fluoroquinolone resistance--an Asian perspective.

  2010cites this paper
• Doripenem: an early look at a carbapenem not yet approved for pediatrics.

  2010cites this paper
• Actividad comparativa de doripenem, meropenem e imipenem en aislados recientes obtenidos durante el estudio de vigilancia epidemiológica COMPACT-España

  2010cites this paper
• [Role of new carbapenems in nosocomial intraabdominal infection].

  2010cites this paper
• Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

  2010cites this paper
• [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].

  2010cites this paper
• A Review of Doripenem for the Treatment of Serious Bacterial Infections

  2010cites this paper
• An Early Look at a Carbapenem Not Yet Approved for Pediatrics

  2010cites this paper
• Carbapenemases: a brief review for pediatric infectious disease specialists.

  2010cites this paper
• Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem

  2009cites this paper
• Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.

  2009cites this paper
• Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.

  2009cites this paper
• Side effects of antibiotics on genetic variability.

  2009cites this paper
• Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.

  2009cites this paper
• Multidrug-Resistant Gram-Negative Infections

  2009cites this paper
• Doripenem: position in clinical practice

  2009cites this paper